Beta Bugs strengthens its position, with backing from existing investors
Beta Bugs Ltd., a leader in Black Soldier Fly (BSF) genetics, today announced that it has raised £800,000 in a new funding round from its existing investors. The funding will support delivery of critical milestones leading to first sales of Hiper-Fly®, in the early part of 2027.
In early 2026, independent trials demonstrated the superiority of Hiper-Fly against industry benchmarks. In August 2026, the company inked an MOU with FreezeM to develop Hiper-Fly as a suspended neonate product, enabling Beta Bugs to supply improved genetics across Europe.
Dr Christopher Richards, Chair of Beta Bugs said:
“This investment reflects investors’ confidence in our vision, based on the progress made over the last 12 months.”. He added, “At the same time, we have confirmed the appointment of Dr Alan Tinch as CEO of Beta Bugs. Alan has extensive experience of commercialising advanced genetics in species such as chickens, pigs and salmon; he knows how to create a profitable business. He has already had significant impact through his membership of our Science Advisory Board.”
Dr Alan Tinch, CEO of Beta Bugs, added:
“The company is at a critical point in its development, and these funds will enable us to move to commercialisation of our outstanding genetics. I am excited to lead the team to deliver the critical milestones ahead and to achieve global leadership in Black Soldier Fly genetics.”
